<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27063860</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN><JournalIssue CitedMedium="Internet"><Volume>131</Volume><PubDate><Year>2016</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res</ISOAbbreviation></Journal><ArticleTitle>Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds.</ArticleTitle><Pagination><StartPage>61</StartPage><EndPage>65</EndPage><MedlinePgn>61-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2016.04.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-3542(16)30203-0</ELocationID><Abstract><AbstractText>Compounds were evaluated for antiviral activity in rhabdomyosarcoma (RD) cells against a recent 2014 clinical isolate of enterovirus D68 (EV-D68), a 1962 strain of EV-68D, rhinovirus 87 (RV-87, serologically the same as EV-D68), and enterovirus 71 (EV-71). Test substances included known-active antipicornavirus agents (enviroxime, guanidine HCl, pirodavir, pleconaril, and rupintrivir), nucleobase/nucleoside analogs (3-deazaguanine and ribavirin), and three novel epidithiodiketopiperazines (KCN-2,2'-epi-19, KCN-19, and KCN-21). Of these, rupintrivir was the most potent, with 50% inhibition of viral cytopathic effect (EC50) and 90% inhibition (EC90) of virus yield at 0.0022-0.0053&#xa0;&#x3bc;M against EV-D68. Enviroxime, pleconaril and the KCN compounds showed efficacy at 0.01-0.3&#xa0;&#x3bc;M; 3-deazaguanine and pirodavir inhibited EV-D68 at 7-13&#xa0;&#x3bc;M, and guanidine HCl and ribavirin were inhibitory at 80-135&#xa0;&#x3bc;M. Pirodavir was active against EV-71 (EC50 of 0.78&#xa0;&#x3bc;M) but not against RV-87 or EV-D68, and all other compounds were less effective against EV-71 than against RV-87 and EV-D68. The most promising compound inhibiting both virus infections at low concentrations was rupintrivir. Antiviral activity was confirmed for the ten compounds in virus yield reduction (VYR) assays in RD cells, and for enviroxime, guanidine HCl, and pirodavir by cytopathic effect (CPE) assays in A549, HeLa-Ohio-1, and RD cells. These studies may serve as a basis for further pre-clinical discovery of anti-enterovirus inhibitors. Furthermore, the antiviral profiles and growth characteristics observed herein support the assertion that EV-D68 should be classified together with RV-87.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Smee</LastName><ForeName>Donald F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>W Joseph</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicolaou</LastName><ForeName>K C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>The Scripps Research Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarbet</LastName><ForeName>E Bart</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Day</LastName><ForeName>Craig W</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA. Electronic address: craig.day@usu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HHSN272201100019I</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000963">Antimetabolites</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010069">Oxadiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010080">Oxazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010091">Oximes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011724">Pyridazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C583099">epidithiodioxopiperazine</NameOfSubstance></Chemical><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>5Z93L87A1R</RegistryNumber><NameOfSubstance UI="D006147">Guanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9DRB973HUI</RegistryNumber><NameOfSubstance UI="C010567">3-deazaguanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9H4570Q89D</RegistryNumber><NameOfSubstance UI="C115201">pleconaril</NameOfSubstance></Chemical><Chemical><RegistryNumber>BML697718K</RegistryNumber><NameOfSubstance UI="C074589">pirodavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>I5V34WG2BE</RegistryNumber><NameOfSubstance UI="C021595">viroxime</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000072283" MajorTopicYN="N">A549 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000963" MajorTopicYN="N">Antimetabolites</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030016" MajorTopicYN="N">Enterovirus D, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006147" MajorTopicYN="N">Guanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010069" MajorTopicYN="N">Oxadiazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010080" MajorTopicYN="N">Oxazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010091" MajorTopicYN="N">Oximes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010849" MajorTopicYN="N">Picornaviridae</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011724" MajorTopicYN="N">Pyridazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012208" MajorTopicYN="N">Rhabdomyosarcoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012229" MajorTopicYN="N">Rhinovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral</Keyword><Keyword MajorTopicYN="N">Enterovirus 71</Keyword><Keyword MajorTopicYN="N">Enterovirus D68</Keyword><Keyword MajorTopicYN="N">Picornavirus</Keyword><Keyword MajorTopicYN="N">Rhinovirus 87</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27063860</ArticleId><ArticleId IdType="mid">NIHMS782813</ArticleId><ArticleId IdType="pmc">PMC5100981</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2016.04.003</ArticleId><ArticleId IdType="pii">S0166-3542(16)30203-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allen LB, Huffman JH, Dan Cook P, Meyer RB, Jr., Robins RK, Sidwell RW. Antiviral activity of 3-deazaguanine, 3-deazaguanosine, and 3-deazaguanylic acid. Antimicrob. Agents Chemother. 1977;12:114&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC352163</ArticleId><ArticleId IdType="pubmed">196546</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnard DL, Bischofberger N, Kim CU, Huffman JH, Sidwell RW, Dougherty JP, Lew W, Williams MA, Yang W. Acyclic phosphonomethylether nucleoside inhibitors of respiratory viruses. Antivir. Chem. Chemother. 1997;8:223&#x2013;233.</Citation></Reference><Reference><Citation>Barnard DL, Hubbard VD, Smee DF, Sidwell RW, Watson KG, Tucker SP, Reece PA. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob. Agents Chemother. 2004;48:1766&#x2013;1772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC400527</ArticleId><ArticleId IdType="pubmed">15105133</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomqvist S, Savolainen C, Raman L, Roivainen M, Hovi T. Human rhinovirus 87 and enterovirus 68 represent a unique serotype with rhinovirus and enterovirus features. J. Clin. Microbiol. 2002;40:4218&#x2013;4223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC139630</ArticleId><ArticleId IdType="pubmed">12409401</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown-Augsburger P, Vance LM, Malcolm SK, Hsiung H, Smith DP, Heinz BA. Evidence that enviroxime targets multiple components of the rhinovirus 14 replication complex. Arch. Virol. 1999;144:1569&#x2013;1585.</Citation><ArticleIdList><ArticleId IdType="pubmed">10486111</ArticleId></ArticleIdList></Reference><Reference><Citation>Caine EA, Partidos CD, Santangelo JD, Osorio JE. Adaptation of enterovirus 71 to adult interferon deficient mice. PLoS One. 2013;8:e59501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3602422</ArticleId><ArticleId IdType="pubmed">23527208</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YC, Yu CK, Wang YF, Liu CC, Su IJ, Lei HY. A murine oral enterovirus 71 infection model with central nervous system involvement. J. Gen. Virol. 2004;85:69&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">14718621</ArticleId></ArticleIdList></Reference><Reference><Citation>Christian KA, Ijaz K, Dowell SF, Chow CC, Chitale RA, Bresee JS, Mintz E, Pallansch MA, Wassilak S, McCray E, Arthur RR. What we are watching--five top global infectious disease threats, 2012: a perspective from CDC's Global Disease Detection Operations Center. Emerg. Health Threats J. 2013;6:20632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3701798</ArticleId><ArticleId IdType="pubmed">23827387</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragovich PS, Prins TJ, Zhou R, Webber SE, Marakovits JT, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Ford CE, Burke BJ, Rejto PA, Hendrickson TF, Tuntland T, Brown EL, Meador JW, 3rd, Ferre RA, Harr JE, Kosa MB, Worland ST. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J. Med. Chem. 1999;42:1213&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pubmed">10197965</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggers HJ. Successful treatment of enterovirus-infected mice by 2-(alpha-hydroxybenzyl)-benzimidazole and guanidine. J. Exp. Med. 1976;143:1367&#x2013;1381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2190224</ArticleId><ArticleId IdType="pubmed">1271013</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Q, Yuan S, Zhang C, Wang Y, Wang Y, He G, Zhang S, Altmeyer R, Zou G. Discovery of itraconazole with broad-spectrum in vitro antienterovirus activity that targets nonstructural protein 3A. Antimicrob. Agents Chemother. 2015;59:2654&#x2013;2665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4394834</ArticleId><ArticleId IdType="pubmed">25691649</ArticleId></ArticleIdList></Reference><Reference><Citation>Greninger AL, Naccache SN, Messacar K, Clayton A, Yu G, Somasekar S, Federman S, Stryke D, Anderson C, Yagi S, Messenger S, Wadford D, Xia D, Watt JP, Van Haren K, Dominguez SR, Glaser C, Aldrovandi G, Chiu CY. A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012-14): a retrospective cohort study. Lancet Infect. Dis. 2015;15:671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6027625</ArticleId><ArticleId IdType="pubmed">25837569</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz BA, Vance LM. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J. Virol. 1995;69:4189&#x2013;4197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189156</ArticleId><ArticleId IdType="pubmed">7769678</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann EC, Jr., Herrmann JA, Delong DC. Prevention of death in mice infected with coxsackievirus A16 using guanidine HCl mixed with substituted benzimidazoles. Antiviral Res. 1982;2:339&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pubmed">6299189</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser L, Crump CE, Hayden FG. In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. Antiviral Res. 2000;47:215&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">10974374</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan F. Enterovirus D68: acute respiratory illness and the 2014 outbreak. Emerg. Med. Clin. North Am. 2015;33:e19&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">26065305</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Yan B, Yeo H, Tan EL, Lee JJ, Ng JK, Chow VT, Alonso S. A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J. Virol. 2012;86:2121&#x2013;2131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3302383</ArticleId><ArticleId IdType="pubmed">22130542</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JY, Shih SR. Cell and tissue tropism of enterovirus 71 and other enteroviruses infections. J. Biomed. Sci. 2014;21:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3995930</ArticleId><ArticleId IdType="pubmed">24602216</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Sheng J, Fokine A, Meng G, Shin WH, Long F, Kuhn RJ, Kihara D, Rossmann MG. Structure and inhibition of EV-D68, a virus that causes respiratory illness in children. Science. 2015;347:71&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4307789</ArticleId><ArticleId IdType="pubmed">25554786</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol. Rev. 2002;26:91&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Midgley CM, Jackson MA, Selvarangan R, Turabelidze G, Obringer E, Johnson D, Giles BL, Patel A, Echols F, Oberste MS, Nix WA, Watson JT, Gerber SI. Severe respiratory illness associated with enterovirus D68 - Missouri and Illinois, 2014. MMWR Morb. Mortal. Wkly. Rep. 2014;63:798&#x2013;799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4584696</ArticleId><ArticleId IdType="pubmed">25211545</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolaou KC, Lu M, Totokotsopoulos S, Heretsch P, Giguere D, Sun YP, Sarlah D, Nguyen TH, Wolf IC, Smee DF, Day CW, Bopp S, Winzeler EA. Synthesis and biological evaluation of epidithio-, epitetrathio-, and bis-(methylthio)diketopiperazines: synthetic methodology, enantioselective total synthesis of epicoccin G, 8,8&#x2032;-epi-ent-rostratin B, gliotoxin, gliotoxin G, emethallicin E, and haematocin and discovery of new antiviral and antimalarial agents. J. Am. Chem. Soc. 2012;134:17320&#x2013;17332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3490634</ArticleId><ArticleId IdType="pubmed">22978674</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste MS, Maher K, Schnurr D, Flemister MR, Lovchik JC, Peters H, Sessions W, Kirk C, Chatterjee N, Fuller S, Hanauer JM, Pallansch MA. Enterovirus 68 is associated with respiratory illness and shares biological features with both the enteroviruses and the rhinoviruses. J. Gen. Virol. 2004;85:2577&#x2013;2584.</Citation><ArticleIdList><ArticleId IdType="pubmed">15302951</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9:1097&#x2013;1105.</Citation><ArticleIdList><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick AK, Binford SL, Brothers MA, Jackson RL, Ford CE, Diem MD, Maldonado F, Dragovich PS, Zhou R, Prins TJ, Fuhrman SA, Meador JW, Zalman LS, Matthews DA, Worland ST. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 1999;43:2444&#x2013;2450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC89498</ArticleId><ArticleId IdType="pubmed">10508022</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938;27:493&#x2013;498.</Citation></Reference><Reference><Citation>Rhoden E, Zhang M, Nix WA, Oberste MS. In vitro efficacy of antiviral compounds against enterovirus D68. Antimicrob. Agents Chemother. 2015 epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4649146</ArticleId><ArticleId IdType="pubmed">26149998</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha-Pereira J, Nascimento MS, Ma Q, Hilgenfeld R, Neyts J, Jochmans D. The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon. Antimicrob. Agents Chemother. 2014;58:4675&#x2013;4681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4136040</ArticleId><ArticleId IdType="pubmed">24890597</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghipour S, Bek EJ, McMinn PC. Selection and characterisation of guanidine-resistant mutants of human enterovirus 71. Virus Res. 2012;169:72&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">22814431</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghipour S, Bek EJ, McMinn PC. Ribavirin-resistant mutants of human enterovirus 71 express a high replication fidelity phenotype during growth in cell culture. J. Virol. 2013;87:1759&#x2013;1769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3554166</ArticleId><ArticleId IdType="pubmed">23175376</ArticleId></ArticleIdList></Reference><Reference><Citation>Schieble JH, Fox VL, Lennette EH. A probable new human picornavirus associated with respiratory diseases. Am. J. Epidemiol. 1967;85:297&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">4960233</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. Journal Infect. Dis. 1974;129:304&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 2010;10:778&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Streeter DG, Witkowski JT, Khare GP, Sidwell RW, Bauer RJ, Robins RK, Simon LN. Mechanism of action of 1-&#x3b2;-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. USA. 1973;70:1174&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC433451</ArticleId><ArticleId IdType="pubmed">4197928</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Meijer A, Froeyen M, Zhang L, Thibaut HJ, Baggen J, George S, Vernachio J, van Kuppeveld FJ, Leyssen P, Hilgenfeld R, Neyts J, Delang L. Antiviral activity of broad-spectrum and enterovirus-specific inhibitors against clinical isolates of enterovirus D68. Antimicrob. Agents Chemother. 2015 epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4649165</ArticleId><ArticleId IdType="pubmed">26369972</ArticleId></ArticleIdList></Reference><Reference><Citation>Tijsma A, Franco D, Tucker S, Hilgenfeld R, Froeyen M, Leyssen P, Neyts J. The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication. Antimicrob. Agents Chemother. 2014;58:6990&#x2013;6992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4249361</ArticleId><ArticleId IdType="pubmed">25199773</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, Yan JJ, Su IJ. Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J. Biomed. Sci. 2000;7:523&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">11060501</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Song Z, Qin B, Zhang X, Chen L, Hu Y, Yuan Z. Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: evaluation of antiviral efficacy in a murine infection model. Antiviral Res. 2013;97:264&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">23295352</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XN, Song ZG, Jiang T, Shi BS, Hu YW, Yuan ZH. Rupintrivir is a promising candidate for treating severe cases of Enterovirus-71 infection. World J. Gastroenterol. 2010;16:201&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806558</ArticleId><ArticleId IdType="pubmed">20066739</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>